Bargagli, Matteo; Vetsch, Andri; Anderegg, Manuel A; Dhayat, Nasser A; Huynh-Do, Uyen; Faller, Nicolas; Vogt, Bruno; Ferraro, Pietro Manuel; Fuster, Daniel G (2023). Tolvaptan treatment is associated with altered mineral metabolism parameters and increased bone mineral density in ADPKD patients. Nephrology, dialysis, transplantation, 38(7), pp. 1645-1654. Oxford University Press 10.1093/ndt/gfac298
Full text not available from this repository. (Request a copy)BACKGROUND
Autosomal-dominant polycystic kidney disease (ADPKD) is characterized by a unique bone and mineral phenotype. The impact of Tolvaptan treatment on mineral metabolism and bone mineral density is unknown.
METHODS
We conducted an analysis in the Bern ADPKD registry, a prospective observational cohort study. Mineral metabolism parameters were measured at baseline and every 12 months thereafter. Bone mineral density was determined by dual-energy X-ray absorptiometry at baseline and after 3 years. Multivariable mixed-effects regression models were applied to assess changes in mineral metabolism parameters and bone mineral density associated with Tolvaptan treatment.
RESULTS
A total of 189 participants (122 without and 67 with subsequent Tolvaptan treatment) were included in the analysis. During follow-up, Tolvaptan treatment was associated with increased bone mineral density at the femoral neck (β 0.092; 95% CI 0.001, 0.183; p = 0.047). In addition, Tolvaptan treatment was associated with higher plasma magnesium (β 0.019; 95% CI 0.001, 0.037; p = 0.037), bicarbonate (β 0.972; 95% CI 0.242, 1.702; p = 0.009) and urine pH (β 0.214; 95% CI 0.056, 0.372; p = 0.008), and lower parathyroid hormone (β -0.191; 95% CI -0.328, -0.053; p = 0.006), 1,25-(OH)2-Vitamin D3 (β -0.126; 95% CI -0.235, -0.164; p = 0.024) and fractional urinary magnesium excretion (β -0.473; 95% CI -0.622, -0.324; p < 0.001).
CONCLUSIONS
Chronic Tolvaptan treatment is associated with increased femoral bone mineral density and significant changes in both mineral metabolism and acid-base parameters in ADPKD patients.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Nephrology and Hypertension |
UniBE Contributor: |
Bargagli, Matteo, Anderegg, Manuel, Dhayat, Nasser, Huynh-Do, Uyen, Faller, Nicolas, Vogt, Bruno, Fuster, Daniel Guido |
Subjects: |
600 Technology > 610 Medicine & health 500 Science > 570 Life sciences; biology |
ISSN: |
1460-2385 |
Publisher: |
Oxford University Press |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
31 Oct 2022 08:42 |
Last Modified: |
01 Jul 2023 00:11 |
Publisher DOI: |
10.1093/ndt/gfac298 |
PubMed ID: |
36309473 |
Uncontrolled Keywords: |
ADPKD Tolvaptan bone mineral density mineral metabolism |
URI: |
https://boris.unibe.ch/id/eprint/174314 |
Actions (login required)
 |
Edit item |